In the second quarter of 2025, Myriad Genetics initiated a review of its long-range growth strategy. While the updated strategy, which is designed to drive accelerated growth and profitability by ...

Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company ...

This news is for Australian Media only Eflornithine is now reimbursed by the government under Australia's Pharmaceutical Benefits Scheme (PBS).

KONZA Health supports and endorses the CMS Digital Health Ecosystem as a bold new vision to support a shared framework for data and access that empowers people, improves care, and accelerates progress ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – The average age of cancer patients is getting younger, as experts are ...